ODI Pharma (ODI) Q4 2025 earnings summary

Executive summary

• Reported a full-year net loss of SEK -5,878,893, a significant increase from SEK -578,059 year-over-year.

• Revenues for the year were SEK 3,362,528, down sharply from SEK 25,328,084 in the prior year, mainly due to temporarily reduced order volumes.

• Strengthened financial position through a directed share issue and a rights issue, raising approximately SEK 4.2 million in total.

• Maintained strong partnerships in Poland, securing product approvals and logistics for future growth.

Financial highlights

• Q4 net sales were SEK 6,461, compared to SEK 7,544,320 in Q4 last year.

• Full-year net sales amounted to SEK 3,110,396, down from SEK 22,285,709 year-over-year.

• Q4 profit after financial items was SEK -1,660,970, compared to SEK -1,111,243 last year.

• Full-year profit after financial items was SEK -5,874,682, compared to SEK -379,470 year-over-year.

• Result per share for the year was SEK -0.32, compared to SEK -0.04 last year.

Outlook and guidance

• Long-term strategy remains focused on expanding in regulated European cannabis markets via a capital-efficient, partner-led model.

• Monitoring opportunities in new geographies while prioritizing operational efficiency.

• Positioned to respond to growth in the European medical cannabis sector.